Historic Change in French Healthcare System from June 15, 2026

From June 15, 2026, there has been a historic change in the French healthcare system. For the first time in the country, next-generation drugs to combat severe obesity - Wegovy (semaglutide) and Mounjaro (tirzepatide) - have been included in the list of reimbursable medicines. The French health insurance (Assurance Maladie) now covers 65% of their cost, making these expensive therapies accessible to the most needy patients.

This decision places France as an absolute leader among European Union countries: so far, no EU state has provided permanent, systematic reimbursement of these drugs through mandatory health insurance. (In some countries, such as Germany or Denmark, coverage was limited or experimental, but not widespread.)

📋 Who is eligible for compensation? Strict but justified criteria

Access to reimbursement is not open to everyone wishing to shed a few kilograms - it is a strictly regulated measure for patients with clinically confirmed severe obesity. The criteria are as follows:

Body mass index (BMI) ≥ 40 (obesity grade III, or “morbid”); Or BMI ≥ 35 in the presence of at least one serious comorbidity - such as type 2 diabetes, arterial hypertension, sleep apnea, severe osteoarthritis, or cardiovascular pathologies. These thresholds are not chosen randomly: it is at these levels that the risk of complications and mortality is highest, and it is here that pharmacological support can provide the greatest reduction in overall mortality and improvement in quality of life.

📝 Mandatory condition: diet and exercise have not helped, and only after a referral from a specialist

Drugs are not prescribed “off the bat.” The patient must first undergo a structured program of lifestyle changes (diet therapy, physical activity, psychological support), and only if these measures have not led to significant weight loss (usually less than 5% in 3-6 months), the doctor may consider drug therapy.

In addition, the primary prescription is not issued by a general practitioner. It must be issued strictly in:

specialized obesity treatment centers (designated as CSO - Centres Spécialisés de l’Obésité); university clinics; endocrinology departments of major hospitals. This ensures that the patient undergoes a comprehensive examination and receives not just a “weight loss shot,” but comprehensive medical support, including monitoring of side effects (nausea, pancreatitis, risks to the thyroid, etc.). After the initial prescription, follow-up may be continued by the treating physician, but with mandatory regular check-up visits to the specialist.

💊 What are the drugs and why are they considered breakthroughs?

Wegovy is semaglutide, a GLP-1 receptor agonist that mimics the intestinal hormone signaling the brain that you are full. It slows stomach emptying and reduces appetite. In clinical trials, patients lost an average of 15% of body weight over 68 weeks. Mounjaro is a newer drug based on tirzepatide, which acts on both GLP-1 and GIP receptors simultaneously. This provides a more pronounced effect: in studies, weight loss reached 20-22% over a similar period. Both drugs are administered subcutaneously once a week. Their main advantage is not just “appetite suppression,” but the reprogramming of metabolic signals, making them effective even in patients with hormonally resistant obesity.

👨‍⚕️ Expert opinion: “This is not a panacea, but a crucial tool”

French endocrinologists and dieticians greeted the news with cautious optimism. Professor Jean-Pierre Desham, head of the French Obesity Study Association (AFERO), noted:

“We have been striving for this for years. Obesity is a chronic disease, not a question of willpower, and its treatment should be as accessible as the treatment of hypertension or diabetes. But we must clearly explain to the public: these drugs are not a substitute for a healthy lifestyle, but an assistant within a long-term therapeutic strategy.” At the same time, some doctors express concern that high demand may lead to supply disruptions, as has already happened in the United States and the United Kingdom. Therefore, the French government has pre-agreed with manufacturers (Novo Nordisk and Eli Lilly) on quotas for the national market.

📊 Who will be affected? Numbers and forecasts

According to the French Ministry of Health estimates, approximately 1 million people - about 1.5% of the country’s population - may be eligible for compensation. However, the total number of people with obesity in France is estimated at 8-9 million, so coverage is strictly limited to the most severe cases.

The cost of a yearly course of Wegovy in France before reimbursement was around €3,600-€4,000, Mounjaro - more expensive (about €5,000). Now, the patient will only pay 35% of this amount (if they do not have additional private insurance, which often covers the rest), reducing annual expenses to €1,200-€1,700 - still significant, but much more affordable than before.

The state budget for these purposes is set at approximately €150-€200 million per year, which, according to economists, will be offset by a reduction in expenses for the treatment of related diseases (diabetes, cardiovascular surgeries, oncology related to obesity) in the long term.

🇪🇺 European precedent and neighbours’ reaction

France has become a pioneer on a pan-European scale. In Germany, Italy, and Spain, negotiations are ongoing for partial reimbursement, but decisions have been postponed until the end of the year. Belgium and the Netherlands are studying pilot projects. Now, with the French experience, other countries will be able to assess the real results - both medical and budgetary.

The European Medicines Agency (EMA) has already approved both drugs for the treatment of obesity, but the decision on financing remains with national systems. The French step may push others to accelerate the process.

💡 Practical advice for patients

If you or your loved ones meet the criteria, here’s what you need to do:

Consult a general practitioner for a preliminary assessment of BMI and comorbidities. Obtain a referral to a specialized obesity center (the list is available on the Assurance Maladie website or through the local regional health agency - ARS). Undergo a comprehensive examination and a trial period of non-drug therapy. Only after the failure of this stage will the specialist prescribe a medication, which can be presented at the pharmacy with insurance notification. It is important to remember: the drugs require regular blood monitoring, liver tests, and periodic eye examinations (due to the risk of vision changes). They are also contraindicated during pregnancy, breastfeeding, and some endocrine tumors.

This step by the French healthcare system is undoubtedly a great victory for patients with severe forms of obesity. But it also raises new questions: how to avoid abuse, how to provide psychological support, and how to prevent a “trend” of injections for healthy individuals. Regulators promise strict monitoring and an annual report on the results.

So France is entering a new era of obesity therapy - cautiously but decisively. And the whole of Europe is watching with interest. 💙